ISSUES IN THERAPY FOR INFLAMMATORY DISEASES OF FEMALE GENITALS

Objective. To evaluate the clinical, immunological, and microbiological efficiency, validity, and safety of livarol in the combination therapy for inflammatory diseases of the female urogenital tract. Design. An open-label, short-term, prospective, randomized study. Material and methods. Real-time polymerase chain reaction, cervical canal discharge microscopy, and examination of local immunity parameters (cell-mediated immunity parameters, sIgA, IgA, IgM, IgG concentrations) and microbiocenosis were made. The antimycotic Livarol was given in accordance with its instruction. Results. The patients with inflammatory diseases of the urogenital tract were found to have significant impairments of cellular and humoral immunity of the genital tract and disorders of vaginal biocenosis. According to the treatment option, the patients were divided into two groups: 1) etiotropic therapy (a basis group); 2) basic therapy in combination with the antimycotic Livarol (a basis + livarol group). A comparison group consisted of 50 apparently healthy women. The most marked normalization of cellular immunity parameters, sIgA levels, and vaginal biotope microbiocenosis was observed in the patients treated with Livarol. Conclusion. The incorporation of the antimycotic livarol for the treatment of inflammatory diseases of the urogenital tract contributes to the normalization of local anti- infective defense factors, the recovery of colonization resistance, and the prevention of vaginal colonization with yeast-like fungi and produces a substantial pharmacoeconomic effect.

inflammatory diseases of the urogenital tract, colonization resistance, antimycotic therapy, livarol, ketoconazole